



TOMÁS J. ARAGÓN, M.D., Dr.P.H.  
Director and State Public Health Officer  
Yes

State of California—Health and Human Services Agency  
California Department of Public Health



GAVIN NEWSOM  
Governor

**Health Advisory: Recommendation for Meningococcal Vaccine (MenACWY) for Men who have Sex with Men (MSM)—Florida Meningococcal Outbreak**

**June 6, 2022**

**Situation Summary**

Since April 2022, in response to an ongoing [outbreak of serogroup C invasive meningococcal disease \(IMD\) in Florida](#), [CDC has encouraged](#) gay, bisexual, and other men who have sex with men (MSM) to:

- Receive quadrivalent meningococcal conjugate vaccine (MenACWY) if they live in Florida
- Talk with their healthcare provider about getting MenACWY if traveling to Florida

MSM have previously been at increased risk for serogroup C IMD, whether during 2015-2016 outbreaks in Southern California and other US urban areas, or outside of outbreaks. Over the next months, MSM and transgender persons who have sex with men in California may have increased exposure to meningococcal infection from travel to Florida or attendance at events with MSM from around the country, including but not limited to Pride events in June 2022.

**Vaccination Recommendations**

CDPH encourages clinicians to offer MenACWY to MSM and transgender persons who have sex with men.

- MenACWY may be particularly beneficial for MSM and who plan to travel to Florida or to attend gatherings (especially crowded venues) with MSM and transgender persons who have sex with men from around the country.
- Persons with ongoing exposure **whose most recent dose of MenACWY was at least 5 years ago should receive a booster dose of MenACWY.**

**Reporting to Public Health**

Clinicians should immediately report suspected cases of IMD to their LHD's [communicable disease control program](#).

**Background**

IMD presents as meningitis or bacteremia, with or without a petechial rash, and can be fatal. [ACIP recommends MenACWY for adults with specific indications](#), including all persons with HIV infection (2-dose primary series 8-12 weeks apart, booster every 5 years).

**For More Information**

[Meningococcal Vaccine Timing for High Risk Populations](#)  
[CDC | Meningococcal Vaccination Information](#)



[CDC | Meningococcal Disease Clinical Information](#)  
[Advisory Committee on Immunization Practices \(ACIP\) | Meningococcal Vaccination](#)  
[Recommendations](#)